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More effective therapy for patients with either muscle-invasive or high-risk
non-muscle-invasive urothelial carcinoma of the bladder (UCB) is an
unmet clinical need. For this, drug repositioning of clinically approved
drugs represents an interesting approach. By repurposing existing drugs,
alternative anticancer therapies can be introduced in the clinic relatively
fast, because the safety and dosing of these clinically approved pharmaco-
logical agents are generally well known. Cationic amphiphilic drugs
(CADs) dose-dependently decreased the viability of a panel of human
UCB lines in vitro. CADs induced lysosomal puncta formation, a hallmark
of lysosomal leakage. Intravesical instillation of the CAD penfluridol in an
orthotopic mouse xenograft model of human UCB resulted in significantly
reduced intravesical tumor growth and metastatic progression. Further-
more, treatment of patient-derived ex vivo cultured human UCB tissue
caused significant partial or complete antitumor responses in 97% of the
explanted tumor tissues. In conclusion, penfluridol represents a promising
treatment option for bladder cancer patients and warrants further clinical
evaluation.
1. Introduction
Urothelial carcinoma of the bladder (UCB) is the fifth
most common cancer in the Western world [1]. Despite
the prevalence and high economic costs of UCB,
this cancer is still relatively understudied [2]. UCB
presents either as non-muscle-invasive (NMIBC) or
as muscle-invasive carcinoma (MIBC), and many
histopathological and molecular subgroups have been
defined [3]. NMIBC patients undergo transurethral
resection of the bladder tumor (TURBT), followed by
adjuvant intravesical instillations with Bacillus Cal-
mette–Guerin (BCG) in patients at high risk of recur-
rence and progression. However, patients do not
always tolerate BCG and the risk of relapse in BCG-
treated patients varies between 30% and 40% [4].
Neoadjuvant cisplatin-based chemotherapy and radi-
cal surgery are the recommended treatment options in
Abbreviations
CAD, cationic amphiphilic drug; MIBC, muscle-invasive bladder carcinoma; NMIBC, non-muscle-invasive bladder carcinoma; TS, explanted
tumor tissue slices; TURBT, transurethral resection of the bladder tumor; UCB, urothelial carcinoma of the bladder.
1Molecular Oncology (2020) ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
9
0
0
1
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
4
.
1
.
2
0
2
1
nonmetastatic MIBC patients. Nevertheless, the 5-year
survival rate is only a mere 50% [5]. For patients with
metastatic UCB, systemic cisplatin-based chemother-
apy is the standard of care [6].
Taken together, more effective therapies for high-
risk NMIBC and advanced or metastatic UCB patients
are warranted.
By repurposing existing drugs, alternative anticancer
therapies can be introduced in the clinic relatively fast,
because the safety and dosing of these clinically
approved pharmacological agents are generally well
known. The risk of clinical failure due to (serious)
adverse effects or reactions is, therefore, strongly
reduced [7]. Consequently, the time needed for bring-
ing the drug from bench to bedside is reduced [8].
Upon meta-analysis, the overall risk ratio of cancer
incidence was reduced among schizophrenia patients,
although findings remain controversial [9,10]. Strik-
ingly, the incidence of UCB in patients with
schizophrenia is significantly reduced when adjusted
for differences in smoking prevalence [9]. Strikingly, a
class of commonly used antidepressants, antihistami-
nes, and antipsychotics—the so-called cationic amphi-
philic drugs (CADs)—were previously found to
preferentially induce cell death in transformed cells
[11]. The most potent CADs, including penfluridol,
display preferential cytotoxicity toward transformed
cells in vitro and potent antitumor activity even as sin-
gle agents in murine tumor models (among others in
breast, colon, pancreatic, and lung carcinoma) [11–17].
We hypothesized that CADs display antitumor activ-
ity in human UCB. We evaluated and compared the
potential antitumor efficacy of multiple CADs in
human UCB cell cultures in vitro, in a preclinical
orthotopic human UCB growth and progression model,
and in cultured, patient-derived UCB tissue ex vivo.
2. Materials and methods
2.1. In vitro
Human UCB cell lines were cultured as described in
Table S1 [18,19].
2.1.1. Cationic amphiphilic drugs
Penfluridol, astemizole, and terfenadine were obtained
from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Penfluridol (P3371) and terfenadine (T9652) were
diluted in absolute EtOH (EMSURE) to a stock
solution of 50 mM. Likewise, astemizole (A2861),
sertindole (S8072), chlorprothixene (C1671), chlorpro-
mazine (C8138), clemastine (SML0445), and loratadine
(L9664) were diluted in dimethyl sulfoxide (DMSO;
Sigma-Aldrich) to a stock solution of 50 mM
(Table S1). Serial dilutions were established by diluting
these stock solutions in the cell-specific medium of the
various cell lines (Table S1).
2.1.2. Viability
Cells were seeded as described previously [18]. Cells
were seeded to reach subconfluency after 24 h and sub-
sequently treated for 2 h with a dose range. After
replacing the medium, cells were incubated at 37 °C for
an additional 24, 48, or 72 h. Subsequently, 20 µL of
MTS reagent was added, and after 2 h, the OD was
measured at 490 nm using the VersaMax ELISA Micro-
plate Reader (Molecular Devices, San Jose, CA, USA).
2.1.3. Live cell count
Cell death was measured after staining for 15 min with
propidium iodide (dead cells; 0.2 lgmL1) and
Hoechst-33342 (live cells; 2.5 lgmL1) at 37 °C
employing Celıgo Cytometer (Nexcelom Bioscience
LLC., Lawrence, MA, USA) according to the manu-
facturer’s manual.
2.1.4. Apoptosis and necrosis
Cells were seeded in a 96-well plate at a density of
10 000 single cells per well with three technical repli-
cates. After 24 h, detection reagent (RealTime-GloTM
Assay) was added. Subsequently, a dose range of pen-
fluridol was added and luminescence and fluorescence
were measured using SpectraMax iD3 (Molecular
Devices, LLC., San Jose, CA, USA).
Fig. 1. CADs reduce viability and clonogenicity in a panel of human bladder cancer cells. Assessment of the viability of T24 (A) and RT-112
(B) cells after treatment with eight different CADs for 40 h (n = 3; six replicates each). Panels C–E represent dose–response experiments
with astemizole, terfenadine, and penfluridol, respectively, on the viability of multiple subconfluent bladder cancer cells. Viability was
measured 48 h after a 2-h treatment. Mean normalized to vehicle-treated cells (n = 3; six replicates each). Clonogenic assay: Multiple
bladder cancer cells were treated for 2 h with a dose range of penfluridol. (F) Representative image of a clonogenic assay UM-UC-3 cells.
(G) The number of colonies was measured using IMAGEJ after 10–14 days of culture (n = 3; three replicates each).
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2.1.5. Clonogenicity
Clonogenic assay was performed as described previously
[18]. In brief, 100 single cells were seeded in a 6-well plate.
After 24 h, cells were treated with a dose range of
penfluridol for 2 h. After replacing themedium, cells were
incubated at 37 °C. After ~ 14 days, cells were fixed with
4% PFA and stained for 10 min with 5% crystal violet.
The number of colonies and colony area were calculated
with IMAGEJ (NIH, Bethesda,MD, USA) software.
Fig. 2. Penfluridol induces cell death in human bladder cancer cells. (A) Real-time apoptosis (luminescence measurement of
phosphatidylserine on outer leaflet of cell membranes with annexin V) and (B) cell death (fluorescence measurement of a DNA-binding dye)
after administration of a dose range of penfluridol. Data presented are mean  SE (n = 3; six replicates each). One-way ANOVA. *P < 0.05;
**P < 0.01; ***P < 0.001. (C) Penfluridol targets lysosomal structures in UM-UC-3 cells (n = 3, 3 replicates each). Representative images of
LAMP-1 (green)- and LGALS1 (red)-/DAPI (blue)-stained UM-UC-3 cells treated for 2 h with a dose range of penfluridol.
Fig. 3. The antitumor effects of penfluridol in an orthotopic murine xenograft model with stable firefly luciferase-2 UM-UC-3 human bladder
cancer cells. Female BALB/c nude mice were inoculated with firefly luciferase-2-labeled UM-UC-3 bladder cancer cells and intravesically
treated with vehicle (n = 8) or penfluridol (n = 9; 100 µM once weekly; equivalent to 130 µgkg1week1). (A) Quantification of the whole-
body total tumor burden in real time (relative light units, RLU). Data are presented as mean  SE. Mann–Whitney U-test. *P < 0.05;
**P < 0.01; ***P < 0.001. (B) Representative bioluminescent images of vehicle- and penfluridol-treated mice at day 29. Representative
images of vehicle (C)- and penfluridol (D)-treated bladders stained with hematoxylin and eosin. Scale bar: 500 and 20 µm, respectively. (E)
The percentage of mice with detectable metastases in the listed organs. (F) Number of metastatic foci per mouse per experimental group.
(G) Metastatic tumor burden per experimental group (RLU). Mann–Whitney U-test. *P < 0.05; **P < 0.01; ***P < 0.001.
4 Molecular Oncology (2020) ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Antitumor activity of CADs in bladder cancer G. van der Horst et al.
2.1.6. Lysosomal membrane permeabilization
60 000 cells were seeded on PET-coated chamber slides
and left for 24 h to adhere. Cells were treated with a dose
range of penfluridol for 2 h. After 24 h, lysosomal mem-
brane permeabilization was detected by staining para-
formaldehyde-fixed cells with LGALS1 and LAMP-1
(Table S1). Confocal images were taken with TCS_SP8.
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2.2. Orthotopic in vivo xenograft model
Female BALB/c nude mice (8 weeks old) were housed
in ventilated cages under sterile conditions according
to Dutch guidelines (evaluated by the Leiden Ethical
Animal Welfare committee; DEC_14212; Table S1).
Human luciferase-expressing UM-UC-3luc2 cells
were inoculated into the bladder as described previ-
ously [19]. For both inoculation of healthy mice and
the xenograft model, mice were intravesically treated
weekly with either vehicle or penfluridol solution
(100 µM equivalent to 130 µgkg1week1). The blad-
der was emptied by mild abdominal massage. Subse-
quently, 50 µL solution was inserted via an
angiocatheter (24 G) and the urethra was closed for
1 h using a suture and thereafter followed by emptying
of the bladder [19]. Bioluminescence imaging was per-
formed using the IVIS Lumina [19]. Quantification of
bioluminescent signals was performed by the LIVING
IMAGE
 (Xenogen, PerkinElmer, Groningen, The
Netherlands) software. Values were expressed as RLUs
in photons/second. Numbers of metastases per animal
were counted by eye from a dorsal and ventral view.
2.3. Ex vivo cultured UCB tissues
Tumor tissues from patients diagnosed with various
stages of UCB were obtained during transurethral
resection of the bladder upon informed consent (evalu-
ated by the Erasmus Medical Ethical Committee
MEC-2014-553) and conform the standards set by the
Declaration of Helsinki. Explanted tumor tissue slices
(TS) were sectioned and cultured as previously
described [20,21].
2.3.1. Histology and immunofluorescence staining
Hematoxylin and eosin staining (H&E) was performed
according to a standard protocol to assess general his-
tology. For immunofluorescence staining, deparaf-
finization was performed via incubation in Histo-Clear
(National Diagnostics, Atlanta, GA, USA, HS-200)
and rehydrated by incubation in a series of decreasing
concentrations of ethanol. Antigen retrieval was per-
formed by cooking the slides in unmasking solution
(Vector Labs, Burlingame, CA, USA, H-3300) in the
pressure cooker. After blocking with 1% BSA (Sigma-
Aldrich, A7906) for 30 min, the slides were incubated
overnight with primary antibody at 4 °C. Next, the
slides were stained for 1.5 h at RT with secondary
antibody and mounted with ProLong Gold Antifade
(Molecular Probes, Thermo Fisher scientific, Breda,
The Netherlands, P36930) (Table S1).
2.3.2. Scoring and inclusion criteria
Upon fixation, paraffin embedding, and sectioning, TS
were stained for H&E, apoptosis (c-CASP-3), prolifer-
ation (PCNA), and cytokeratins (KRT) [21]. Stained
sections were scanned with a slide scanner and evalu-
ated with CaseViewer. Immunohistochemical evalua-
tions were based on visual estimations from complete
histological tissue sections. Confocal images were
taken from representative regions.
Criteria for the inclusion of UCB tissue are as fol-
lows: (a) diagnosis of UCB in TS is confirmed by the
pathology report; (b) majority of directly fixed and/or
vehicle-treated TS contain tumor cells; and (c) size of
obtained material is sufficient to perform at least vehicle
and 1 CAD dosage. First, H&E-stained TS were scored
for overall quality (score 0: good quality; 1: poor tissue
integrity and quality in > 50% of TS area; 4: tissue com-
pletely degraded or fragmented). Then, sections were
scored for the presence of apoptosis (c-CASP-3+ tumor
cells) and fragmented cytokeratin (loss of cell integrity)
(score 0: sporadic; 1: multiple clusters). Finally, TS were
scored for the presence of PCNA (score 1: < 50% of
KRT+ cells displayed nuclear PCNA). Total score:
cumulative individual scores (Fig. S4).
2.4. Statistics
Analysis was performed using Graphpad Prism 7.0
(Graphpad software, San Diego, CA, USA) and Excel;
for in vitro assays, one-way ANOVA and Bonferroni
post-hoc test; for in vivo assays, Mann–Whitney U-
tests; and for ex vivo assays, chi-squared test for cate-
gorical data with more than two categories.
*P < 0.05;**P < 0.01;***P < 0.001.
3. Results
3.1. Cationic amphiphilic drugs induce
lysosomal-dependent cell death in vitro
To identify CADs that display antitumor effects, 8
CADs were selected—at least in part—based on a
library screen on lung cancer and on the NCI drug
sensitivity database [22]. These CADs were initially
tested for their effect on viability of T24 and RT-112
human UCB cells in vitro. The CADs penfluridol,
astemizole, and terfenadine induced the strongest anti-
tumor effects upon short-term exposure (Fig. 1A,B;
Fig. S1A–D). Subsequently, short-term exposure to a
dose range of these CADs also led to a dose-depen-
dent inhibition in viability of a panel of UCB cells
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(Fig. 1C–E; Fig. S1E–G). Viability was decreased
when a confluent layer of UCB cells was exposed to a
dose range of penfluridol (Fig. S1J). Furthermore,
penfluridol significantly decreased the clonogenicity of
multiple UCB cell lines (Fig. 1F,G; Fig. S2A–D).
Since we observed strongest antitumor potential with
penfluridol, this compound was used in other disease
models in vivo and ex vivo.
Table 1. Patient characteristics. Tumor tissues from 57 patients diagnosed with various stages of UCB were obtained during transurethral
resection of the bladder (TURBT upon informed consent, MEC-2014-553). Tumor tissues from 39 patients were included according to the
tissue quality inclusion criteria. Disease stage, grade, and presence of CIS and detrusor were determined by a pathologist. Patient #40 is a
patient diagnosed with prostate carcinoma Gleason grade 3 + 4 with no history of UCB. NA, not applicable; BCG, Bacillus Calmette–Guerin.
Patient
no
Disease
stage
Disease
grade Tumor Recurrence frequency Cis present Detrusor present
Previous
treatment
Previous
treatment
modality Gender Age
1 Ta G1 Primary NA Unknown Yes No NA Male 75
2 Ta G1 Primary NA Unknown Yes No NA Male 71
3 Ta G1 Recurrence > 1/
year
Unknown Yes Unknown Unknown Male 72
4 Ta G1 Primary NA Unknown Yes No NA Female 69
5 Ta G1 Primary NA Unknown No No NA Male 62
6 Ta G1 Recurrence > 1/year Unknown No Yes Nephroureterectomies Male 63
7 Ta G2 Primary NA Unknown Yes No NA Male 76
8 Ta G2 Primary NA No Yes No NA Male 67
9 Ta G2 Recurrence > 1/year No Yes Yes TURBT only Male 86
10 Ta G2 Recurrence > 1/year No Yes Yes Chemotherapy Male 56
11 Ta G2 Recurrence > 1/year No Yes Yes BCG Male 87
12 Ta G2 Recurrence > 1/year No Yes Yes Nephroureterectomies Male 62
13 Ta G2 Primary NA No Unknown No NA Male 39
14 Ta G2 Recurrence > 1/year No Yes Yes BCG Male 59
15 Ta G2 Primary NA No Yes No NA Female 69
16 Ta G2 Recurrence > 1/year No Yes Yes Chemotherapy Female 53
17 Ta G2 Recurrence > 1/year No Yes Yes Chemohyperthermia Male 57
18 Ta G2 Primary NA No Yes No NA Male 79
19 Ta G2 Primary NA No Yes No NA Male 73
20 Ta G2 Recurrence < 1/year No Yes Yes Chemotherapy Male 75
21 Ta G2 Recurrence > 1/year No Yes Yes BCG Female 59
22 Ta G2 Recurrence Unknown No Yes Yes
Chemoradiation Male 84
23 Ta G3 Primary NA No Yes No NA Male 75
24 Ta G3 Recurrence > 1/year No No Yes BCG Male 76
25 Ta G3 Primary NA Unknown No No NA Male 56
26 Ta Unknown Primary < 1/year No Unknown No NA Female 53
27 T1 G2 Recurrence < 1/year Unknown No No NA Male 86
28 T1 G2 Recurrence > 1/year No Yes Yes BCG Male 74
29 T1 G2 Primary NA Yes Yes No NA Male 67
30 T1 G2 Primary NA No Yes No NA Male 55
31 T1 G3 Primary NA No Yes Yes TURBT only Male 66
32 T1 G3 Recurrence > 1/year No Yes Yes BCG Male 52
33 T1 G3 Primary NA No No No NA Female 67
34 T1 G3 Primary NA Unknown Yes No NA Male 81
35 T2 G3 Primary NA No Yes No NA Male 74
36 T2 G3 Primary NA Yes Yes No NA Male 58
37 T2 G3 Recurrence > 1/year Yes Yes No NA Male 72
38 T2 G3 Primary NA Unknown Yes No NA Male 66
39 T2 High
grade
Primary NA Unknown Yes No NA Male 64
40 T3 Gl3 + 4 Primary NA NA NA Yes LHRH agonist Male 65
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Penfluridol treatment resulted in redistribution of
phosphatidylserine from the internal to external mem-
brane surface, an early indicator of apoptosis. This was
followed by lysis of the cell as measured with a DNA-
binding dye (Fig. 2A,B). For the higher dosage
(100 µM), only a small increase in apoptosis was
observed, and already loss of membrane integrity was
observed within 2 h. Furthermore, lysosomal LGALS1
puncta formation, a hallmark of lysosomal leakage, was
found in penfluridol-treated cells (Fig. 2C) [11,12,23,24].
3.2. Penfluridol inhibits UCB growth and
metastasis in a preclinical orthotopic xenograft
model
In order to evaluate the antitumor effects of penfluri-
dol in a preclinical xenograft mouse model, firefly
luciferase-2-expressing human UM-UC-3luc2 cells
were inoculated in the bladder of female immunodefi-
cient mice (BALB/c nude) [19]. Four days after tumor
cell inoculation, tumor burden was assessed by whole-
body bioluminescence imaging (BLI) and properly
inoculated mice were equally distributed among two
groups with similar median tumor burden (Fig. S3A,
B) [19]. At this stage, bladder tumor cells have not
yet invaded the muscle layer of the murine bladder.
Subsequently, the mice were treated by weekly intrav-
esical instillations of penfluridol or vehicle solution.
Penfluridol significantly reduced total tumor burden
by 63% (Fig. 3A,B). No significant changes were
observed in body weight (Fig. S3C). At day 29, mice
were sacrificed and size and weight of the bladders of
penfluridol-treated mice were diminished compared
with vehicle-treated animals (Fig. S3D,E). As
expected, histological examination revealed large
orthotopically growing tumors in vehicle-treated mice
with invasion of the tumors into the surrounding con-
nective tissue and muscle layers (Fig. 3C). In contrast,
in penfluridol-treated mice no tumor invasion into the
bladder muscle layer was observed and large necrotic
regions in tumor tissues at the luminal side of the
bladder were detected (Fig. 3D). All vehicle-treated
mice developed metastatic disease with an average of
6.8 metastases/mouse, while only 33% of the penfluri-
dol-treated animals developed distant metastases with
an average of 4.3/mouse (Fig. 3E). Metastases were
observed in the lungs, reproductive system, liver,
intestinal or mesenteric lymph nodes, pancreas, bone,
and spleen lymph nodes (Fig. S3F). Both the number
of metastases/mouse and metastatic tumor burden
were significantly decreased in penfluridol-treated mice
(Fig. 3F,G).
3.3. Antineoplastic response of penfluridol in
ex vivo cultured, patient-derived cancer tissue
slices
Next, we examined the antineoplastic effect of pen-
fluridol in our ‘near-patient’ model, that is, ex vivo cul-
tured patient-derived UCB tissue slices [21]. Tumor
tissues from 57 patients diagnosed with different stages
of bladder carcinoma were obtained during transure-
thral resection of the bladder (TURB) procedures.
Tumor tissues from 39/57 patients (68%) were
included according to a predefined set of tissue quality
criteria (see Materials and methods: Histology and
immunofluorescence staining; Table 1).
Tumor tissues were treated with vehicle solution or
a dose range of penfluridol (n = 18) for 3 days. When
tumor biopsy material was limited (n = 21), explanted
tumor tissues were cultured in the presence of vehicle
solution or 100 µM penfluridol for 3 days.
Fig. 4. Ex vivo treatment of cultured human bladder cancer slices with penfluridol. Heat maps showing median cumulative scores of the
bladder cancer slices per condition per patient. Multiple explanted tissue slices were cultured for each condition. Cumulative score is based
on histological evaluation of entire tissue slice (TS; see Fig S4). TS were scored in four categories: (1) overall quality based on H&E staining,
(2) the presence of apoptotic cells [cleaved caspase 3+(c-CASP-3+)/keratin+ (KRT+) cells], (3) cancer cell debris (fragmented keratin), and (4)
nuclear proliferation based on proliferation cell nuclear antigen (PCNA). TS received a score of either 0 or 1 for each category. For category
1, TS received a score of 1 when > 50% of tissue was fragmented/degraded. For categories 2 and 3, TS received a score of 1 when
multiple clusters were observed. For category 4, TS received a score of 1 when < 50% of KRT+ cells in the TS displayed nuclear PCNA.
Cumulative score was calculated as the sum of the 4 categories; median cumulative scores are shown (see also Fig. S4). Explanted tumor
slices were ex vivo cultured with vehicle solution or penfluridol (100 µM for A–B and a dose range for C–D) for 3 days. Chi-squared test for
categorical data with more than two categories. P value = 4.36424E11. (B) Representative images of bladder cancer slices obtained from a
patient diagnosed with NMIBC stage T1 grade 2 (#28) after 3 days in the presence of vehicle solution or penfluridol (100 µM). Complete
loss of tumor cells was observed in five patient-derived tumor explants (#9, 28, 29, 31, and 35). Significant reduction was found in 30
patient-derived tumor explants (#1–8, 10–15, 17, 20, 22–27, 30, 32–34, and 36–39). A partial response was observed in 3 patient-derived
tumor explants (#18, 19, and 21). No response was observed in one patient-derived tumor explant (#16). (D) Representative images of
bladder cancer tissue slices obtained from a patient diagnosed with NMIBC stage T1 grade 2 (#9) after 3 days in the presence of vehicle
solution or a dose range of penfluridol. c-CASP-3 and PCNA: green; panKRT: red; and DAPI: blue. Scale bar: 25 µm.
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Culturing of the tumor tissue slices under control
conditions only marginally affected tissue integrity and
viability or not at all, as indicated by marginal differ-
ences in immunohistochemical localization of frag-
mented cytokeratin (indicative of cancer cell debris),
apoptotic cells (c-CASP-3), and proliferating cells
(PCNA) compared to directly fixed tissue (scoring
method in Fig. S4 and results in Fig. S5). In almost
all patients (35/39), strong changes were observed after
treatment with penfluridol, ranging from complete loss
of tumor to significant reduction of the tumor
(Fig. 4A). An overall reduction in the number of UCB
cells, proliferating cells (PCNA), increased numbers of
apoptotic cells (c-CASP-3), and significantly increased
amounts of fragmented cytokeratins were observed (P
value = 4.36424E11, Χ2 test). In tissue slices obtained
from only three patients, partial antineoplastic
responses were registered (e.g., an induction of apopto-
sis). In tissue slices obtained from one patient (1/39),
no response to the treatment was found. The effect of
a dose range of penfluridol revealed that, starting from
12.5 µM, major antineoplastic changes were observed
(Fig. 4C,D).
3.4. Penfluridol has no effect on normal
urothelium
Intravesical treatment represents a potential alternative
route of administration of CADs for the treatment of
localized bladder cancer. In order to evaluate safety of
penfluridol instillations on normal urothelium, a dose
range of penfluridol was administered to non-tumor-
bearing mice by weekly intravesical treatment (Fig. 5A).
Histological analyses revealed no detectable changes of
normal murine urothelium after multiple doses of
intravesical penfluridol (Fig. 5B–D). Moreover, while
penfluridol treatment of ex vivo cultured patient-derived
UCB tissues caused significant antitumor effects, adja-
cent ‘normal’ human urothelium was not or only mar-
ginally affected (Fig. S6A,B). No changes were
observed in epithelial tissue integrity, the proliferation
index (PCNA), viable epithelial cell numbers, or frag-
mented KRT, despite a mildly increased apoptotic
response (Fig. S6A). Because matched normal urothe-
lium samples are scarce, we assessed the effect of pen-
fluridol on ‘normal’ urothelium of a prostate cancer
patient with no history of bladder carcinoma. Again, no
detectable tissue integrity changes were observed in the
penfluridol-treated human urothelium versus vehicle-
treated urothelium. Limited c-CASP-3+ cells were only
observed in the penfluridol-treated normal urothelium
layers, but no detectable changes of urothelium tissue
integrity were found (Fig. 5E).
4. Discussion
In this study, we provide compelling evidence that
CADs display significant antitumor effects in multiple
preclinical bladder cancer models, that is, cultured
human UCB cells in vitro, an orthotopic preclinical
xenograft model of UCB growth and metastasis
in vivo, and patient-derived ex vivo cultured UCB tis-
sues. Screening of eight different CADs in a panel of
cultured human UCB cell lines identified penfluridol as
a potent candidate anticancer agent. We observed that
the antitumor properties of penfluridol in human UCB
may rely on rapid destabilization of lysosomal struc-
tures in human UCB cells.
Our data in UCB are in line with the observed anti-
neoplastic effects of CADs in other solid tumors [11–
17]. Other antineoplastic mechanisms of this class of
compounds may also play a role, including antimigra-
tory and invasion effects, cell cycle effects, changes in
cholesterol homeostasis, autophagy, immune modula-
tion, or nonhomologous end joining (reviewed in
{Shaw, 2019 #2068} [25–28].
Cationic amphiphilic drugs have been shown to
induce lysosome-dependent cell death mediated by
lysosomal cathepsin proteases leaking from the desta-
bilized lysosomes to the cytosol in other tumors [29–
31]. Selectivity of the CADs for transformed cells is
due to the lower constitutional acid sphingomyelin
levels in their lysosomes compared to healthy cells.
CADs reduce ASM levels to the point of lysosomal
membrane permeabilization which leads to lysosome-
dependent cell death specifically in transformed cells
[29,30,32]. Selectivity of CADs for transformed blad-
der epithelial cells is further substantiated by the
observed lack of adverse effects of CAD treatment on
normal urothelium, which was not (or only margin-
ally) affected after intravesical administration of a
same dose of penfluridol in a non-tumor-bearing
in vivo model and administration of penfluridol to
ex vivo cultured normal human bladder tissue.
In our preclinical disease model of orthotopically
growing human UCB, weekly intravesical instillation
with penfluridol significantly reduced tumor progres-
sion, invasion, and formation of distant metastases.
Our preclinical data demonstrate that effective delivery
of penfluridol can be achieved by instillation in the
bladder, thus mimicking the clinical use of standard-
of-care pharmacological agents mitomycin C or BCG.
This way, potential adverse systemic side effects of this
class of antipsychotic drugs may be largely avoided.
For UCB patients that present with a disease con-
fined to the mucosa (stage Ta, CIS) or submucosa
(stage T1), treatment consists of transurethral resection
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Fig. 5. Evaluation of the effect of penfluridol on normal murine or human urothelium integrity. (A) Average body weight (mean  SE) of
non-tumor-bearing female BALB/c nude mice treated intravesically with vehicle (n = 5) or penfluridol solution (n = 5; 100 µM once weekly
for 4 weeks; equivalent to 130 µgkg1week1). One-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001. Representative overview images
of H&E-stained murine bladders of vehicle-treated (B) and 100 µM penfluridol-treated (C) mice. (D) Representative images of vehicle- and
penfluridol-treated, non-tumor-bearing murine bladders. c-CASP-3 and PCNA: green; panKRT: red; and DAPI: blue. Scale bar: H&E: 20 µm; IF
staining: 25 µm. (E) Representative images of nontransformed ‘normal’ urothelium in tissue slices obtained from a patient with prostate
cancer with no history of bladder carcinoma, treated either with vehicle solution or with 100 µM penfluridol for 3 days (#40). c-CASP-3 and
PCNA: green; panKRT: red; and DAPI: blue. Scale bar: 25 µm.
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of the bladder (TURB) followed by an immediate
postoperative intravesical instillation with chemother-
apy. In patients who are at intermediate or high risk
of recurrence, maintenance treatment with intravesical
chemo- or immunotherapy is advocated in the guide-
lines. In general, chemotherapy with mitomycin C or
epirubicin for 1 year (4 weekly instillations followed
by 6–8 monthly instillations) is indicated in intermedi-
ate-risk patients, whereas high-risk patients are treated
with 1 to 3 years of Bacillus Calmette–Guerin (BCG)
[33]
Patients in whom NMIBC recurs after TURB and
BCG treatment, and who have BCG-unresponsive dis-
ease, are unlikely to respond to further BCG therapy
and may need a cystectomy. The alternative treatment
option is lifelong cystoscopic surveillance, and frequent
TURB re-operations are necessary. Obvious downsides
of radical cystectomy are that it is a major surgical
procedure with substantial cost and a negative impact
on the quality of life of patients. If feasible, patients
often prefer a bladder sparing treatment and new
intravesical therapies are being developed in clinical
trials [34].
Despite these new developments, only valrubicin—a
doxorubicin analog—was FDA-approved for BCG-re-
fractory CIS [35]. Based on the growing body of evi-
dence and the previously established safety profile of
CADs as FDA-approved drugs, penfluridol appears to
be a promising anticancer compound, especially when
systemic exposure is reduced by intravesical adminis-
tration to patients with (recurrent) high-risk bladder
cancer. Taken together, our current findings emphasize
the need for a clinical trial that will address safety and
antitumor efficacy aspects of intravesical penfluridol in
organ-confined bladder cancer.
5. Conclusions
Cationic amphiphilic drugs like penfluridol signifi-
cantly reduced UCB cell viability. Weekly bladder
instillations of penfluridol resulted in significant
decreased tumor growth, progression, and metastasis
in vivo. Treatment of cultured patient-derived UCB tis-
sue slices with penfluridol resulted in significant antitu-
mor responses ranging from complete loss of tumor to
significant reduction. Normal urothelium, when treated
with penfluridol, was not at all or only marginally
affected upon instillation of CADs in a preclinical
UCB in vivo model and cultured normal human blad-
der tissue slices ex vivo.
Taken together, penfluridol is a promising anti-
cancer agent in human UCB and clinical studies are
required to determine whether this FDA-approved
antipsychotic agent can provide a benefit to patients
with UCB.
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